Truist analyst Srikripa Devarakonda cut her rating on the stock to hold, after being at buy for the past 11 months. She ...
Truist analyst Srikripa Devarakonda raised the firm’s price target on Scholar Rock (SRRK) to $45 from $36 and keeps a Buy rating on the shares. Competitor Biohaven’s (BHVN) Phase 3 trial in ...
Truist Financial analyst Srikripa Devarakonda reiterated a Buy rating on Edgewise Therapeutics (EWTX – Research Report) today. The company’s ...
20don MSN
AbbVie Inc.’s disappointing trial results for its new schizophrenia drug bode well for rival Bristol Myers Squibb Co., ...
Truist Financial analyst Srikripa Devarakonda maintained a Buy rating on Scholar Rock Holding (SRRK – Research Report) today and set a price ...
Truist analyst Srikripa Devarakonda notes that AbbVie (ABBV) announced negative trial results for emraclidine in dual Phase 2 schizophrenia trials, which the firm sees as a negative for AbbVie and ...
Srikripa Devarakonda; Analyst; Truist Securities, Inc. Good afternoon and welcome to AbCellera's Q3 2024 business update conference call. My name is Tamia and I will facilitate the audio portion ...
Investor's Business Daily on MSN1mon
Why Amgen's Obesity Drug — And $5 Billion Opportunity — Led To A DowngradeAmgen stock dipped Monday after an analyst downgraded shares, saying the $5 billion opportunity for its weight-loss drug, ...
"ABBV's pain is BMY's gain," Truist Securities analyst Srikripa Devarakonda said in a note released Tuesday. "We see this as a negative for AbbVie (ABBV, Buy) and a positive for Bristol (BMY ...
Srikripa Devarakonda; Analyst; Truist Securities, Inc. Good afternoon and welcome to AbCellera's Q3 2024 business update conference call. My name is Tamia and I will facilitate the audio portion of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback